Boston Scientific to acquire Penumbra in $14.5B push into thrombectomy and neurovascular care
Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valued at about $14.5 billion (Penumbra at $374/share), creating a scaled entry into mechanical thrombectomy and neurovascular therapies. The transaction finances roughly 73% cash and 27% Boston Scientific stock (about $11 billion cash financed with cash on hand and new debt) and is expected to close in 2026 pending stockholder and regulatory approvals. Penumbra reported about $1.4 billion in revenue for 2025. Penumbra stockholders may elect cash or Boston Scientific shares; Adam Elsesser plans to take Boston Scientific stock for all his Penumbra shares. The deal is dilutive to GAAP earnings in the near term and to adjusted EPS in the near term, with accretion expected in later years.
